タイトル無し
スポンサーリンク
概要
- 論文の詳細を見る
A potent anti-cancer agent, 5-flurouracil has been generally given through parenteral routes. In the clinical practice of cancer chemotherapy, many cases are actually considered to be suitable as candidates of oral administration of this particular drug. To solve this practical problem, we studied on the absorption and the organ distribution of this agent, using S-D rats, comparing the two administration methods, namely oral and intravenous administration. Also, pharmacokinetic studies were performed on two patients with advanced breast cancer, to evaluate the above-mentioned two administration routes.<BR>The rats were sacrificed 0.5, 1, 2, 4, 6 and 8 hours after oral or intravenous administration of 768×10<SUP>-6</SUP> mol of 5-fluorouracil or 5-fluorouridylic acid, to obtain organ tissue homogenates. The bioassay technique using staphylococcus aureus 209-p was employed to know the drug concentration levels. The following results were obtained:<BR>1. Both intravenous and oral administration of 5-fluorouracil produced almost same level of organ distribution curve, except the mucous membrane of the stomach which showed markedly high level of the drug concentration approximately 12 hours following the oral administration.<BR>2. The oral administration of 5-fluorouridylic acid showed extremely low organ distribution curve, comparing its intravenous administration.<BR>3. Pharmacokinetic data obtained from the two volunteer patients showed significantly high bioavailability after the oral administration of 5-fiuorouracil, in comparison with the intravenous administration.
- 一般社団法人 日本臨床薬理学会の論文
著者
関連論文
- 弗化ピリミジン化合物・作用機序 : 臨床応用と関連して
- 38.乳房の顆粒細胞腫(C群 : 乳腺, 示説, 第17回日本臨床細胞学会秋期大会抄録)
- 18.乳頭分泌液にて発見した早期乳癌の2例(細胞診が診断にきわめて有効であった例, 示説カンファレンスII, 第14回日本臨床細胞学会秋季大会講演要旨)
- 16.豊胸術後に発生した乳癌の細胞像(稀有なる症例の細胞像, 示説カンファレンスI, 第14回日本臨床細胞学会秋季大会講演要旨)
- 病院における研修計画(薬学教育6年制におけるカリキュラムを考える)
- 乳腺線維腺腫と葉状嚢胞腺腫 (乳腺良性疾患の治療)
- 新方式の液晶コレステロ-ル膜による"Auto-thermography"
- タイトル無し
- タイトル無し
- タイトル無し
- タイトル無し
- タイトル無し
- タイトル無し
- Clinical Studies on the Oral Administration of 5-Fluorouracil with Reference to the Control of Advanced Breast Cancer